Evolus (NASDAQ:EOLS) Hits New 1-Year High - Time to Buy?

Shares of Evolus, Inc. (NASDAQ:EOLS - Get Free Report) hit a new 52-week high during mid-day trading on Monday . The company traded as high as $17.81 and last traded at $17.78, with a volume of 358373 shares changing hands. The stock had previously closed at $16.90.

Wall Street Analyst Weigh In

EOLS has been the topic of a number of analyst reports. Needham & Company LLC reissued a "buy" rating and set a $22.00 target price on shares of Evolus in a report on Friday, September 13th. Barclays boosted their price target on shares of Evolus from $16.00 to $20.00 and gave the company an "overweight" rating in a research report on Friday, September 13th. HC Wainwright restated a "buy" rating and set a $27.00 price target on shares of Evolus in a research report on Thursday, October 3rd. Finally, Cantor Fitzgerald restated an "overweight" rating on shares of Evolus in a research report on Monday, September 16th.

Evolus Price Performance

The business's 50-day moving average price is $15.49 and its 200 day moving average price is $13.37. The stock has a market capitalization of $1.08 billion, a PE ratio of -16.82 and a beta of 1.31. The company has a debt-to-equity ratio of 6.26, a quick ratio of 2.67 and a current ratio of 2.92.

Evolus (NASDAQ:EOLS - Get Free Report) last announced its earnings results on Wednesday, July 31st. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.02). The company had revenue of $66.91 million for the quarter, compared to the consensus estimate of $65.06 million. Research analysts forecast that Evolus, Inc. will post -0.64 earnings per share for the current year.

Insider Buying and Selling

In related news, CFO Sandra Beaver sold 3,276 shares of the company's stock in a transaction on Friday, September 6th. The shares were sold at an average price of $14.98, for a total value of $49,074.48. Following the completion of the transaction, the chief financial officer now directly owns 148,502 shares in the company, valued at approximately $2,224,559.96. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Evolus news, CFO Sandra Beaver sold 3,276 shares of the company's stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $14.98, for a total transaction of $49,074.48. Following the completion of the sale, the chief financial officer now directly owns 148,502 shares in the company, valued at $2,224,559.96. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CMO Tomoko Yamagishi-Dressler sold 5,631 shares of the company's stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $15.85, for a total transaction of $89,251.35. Following the sale, the chief marketing officer now owns 82,375 shares of the company's stock, valued at approximately $1,305,643.75. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 6.10% of the stock is owned by company insiders.

Institutional Trading of Evolus

Several institutional investors have recently added to or reduced their stakes in EOLS. Sierra Summit Advisors LLC purchased a new stake in Evolus during the fourth quarter valued at about $119,000. Los Angeles Capital Management LLC bought a new position in shares of Evolus during the first quarter valued at about $1,907,000. China Universal Asset Management Co. Ltd. raised its stake in shares of Evolus by 65.8% during the first quarter. China Universal Asset Management Co. Ltd. now owns 10,969 shares of the company's stock valued at $154,000 after acquiring an additional 4,355 shares during the last quarter. Principal Financial Group Inc. raised its stake in shares of Evolus by 141.7% during the first quarter. Principal Financial Group Inc. now owns 34,785 shares of the company's stock valued at $487,000 after acquiring an additional 20,391 shares during the last quarter. Finally, BNP Paribas Financial Markets raised its stake in shares of Evolus by 84.2% during the first quarter. BNP Paribas Financial Markets now owns 405,931 shares of the company's stock valued at $5,683,000 after acquiring an additional 185,532 shares during the last quarter. 90.69% of the stock is currently owned by hedge funds and other institutional investors.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.